Last checked at 
Angle PLC - Surrey, England-based medical diagnostics company - Notes University of Maryland Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute has published results of work undertaken in preclinical models of triple-negative breast cancer. Findings show isolation of live circulating tumour cells from a simple blood draw, using Angle's Parsortix system, can provide rapid information on patient response to existing chemotherapy treatments that can target metastasis more effectively than tumour growth.
Chief Executive Andrew Newland says: "We are pleased to report on the use of the Parsortix system for the isolation of live CTCs in pre-clinical TNBC models, uncovering the potential to provide rapid information on how a patient is responding to a therapy. Angle's ability to provide actionable insight could help patients with limited treatment options and could help to identify already approved drugs that could target highly metastatic and hard-to-treat cancers, such as TNBC."
Current stock price: 107.03 pence
12-month change: up 30%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
